TY - JOUR
T1 - In vitro activity of recombinant lysostaphin in combination with linezolid, vancomycin and oxacillin against methicillin-resistant Staphylococcus aureus
AU - Narasimhaswamy, Nagalakshmi
AU - Bairy, Indira
AU - Shenoy, Gautham
AU - Bairy, Laxminarayana
N1 - Publisher Copyright:
© 2017, Tehran University of Medical Science, All rights reserved.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Background and Objectives: The antimicrobial combination with synergistic mechanism is recommended to provide broad-spectrum coverage, and prevent the emergence of resistant mutants. In the present study, the synergistic activity of lysostaphin with linezolid, oxacillin and vancomycin, against methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates was determined. Materials and Methods: Seventy-three MRSA isolates collected from clinical specimens were tested, for in vitro synergistic activity of lysostaphin with linezolid, vancomycin and oxacillin, by checkerboard assay. Results: Lysostaphin showed synergistic activity with linezolid and oxacillin, against all MRSA isolates, tested in the present study. Whereas, only 19.1% of the isolates showed synergistic activity with vancomycin and remaining 80.9% of the MRSA isolates showed additive activity. Conclusion: Lysostaphin causes rapid lysis of S. aureus. Combination therapies that include linezolid and lysostaphin could be used in life-threatening infections, such as endocarditis to increase the early in vivo activity of the antibiotics, and to prevent the emergence of linezolid resistant mutants. Further, in vivo studies are warranted to confirm our results.
AB - Background and Objectives: The antimicrobial combination with synergistic mechanism is recommended to provide broad-spectrum coverage, and prevent the emergence of resistant mutants. In the present study, the synergistic activity of lysostaphin with linezolid, oxacillin and vancomycin, against methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates was determined. Materials and Methods: Seventy-three MRSA isolates collected from clinical specimens were tested, for in vitro synergistic activity of lysostaphin with linezolid, vancomycin and oxacillin, by checkerboard assay. Results: Lysostaphin showed synergistic activity with linezolid and oxacillin, against all MRSA isolates, tested in the present study. Whereas, only 19.1% of the isolates showed synergistic activity with vancomycin and remaining 80.9% of the MRSA isolates showed additive activity. Conclusion: Lysostaphin causes rapid lysis of S. aureus. Combination therapies that include linezolid and lysostaphin could be used in life-threatening infections, such as endocarditis to increase the early in vivo activity of the antibiotics, and to prevent the emergence of linezolid resistant mutants. Further, in vivo studies are warranted to confirm our results.
UR - http://www.scopus.com/inward/record.url?scp=85034668138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85034668138&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85034668138
SN - 2008-3289
VL - 9
SP - 208
EP - 212
JO - Iranian Journal of Microbiology
JF - Iranian Journal of Microbiology
IS - 4
ER -